NCT02714634View on ClinicalTrials.gov

Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide

PHASE4RecruitingINTERVENTIONAL
Enrollment

286

Participants

Timeline

Start Date

March 30, 2016

Primary Completion Date

March 31, 2029

Study Completion Date

March 31, 2029

Conditions
Rheumatoid ArthritisInsufficient Response to Methotrexate or Leflunomide
Interventions
DRUG

Methotrexate + targeted therapy administration

"* Methotrexate or leflunomide + adalimumab or~* Methotrexate or leflunomide + certolizumab or~* Methotrexate or leflunomide + etanercept or~* Methotrexate or leflunomide + golimumab or~* Methotrexate or leflunomide + infliximab or~* Methotrexate or leflunomide + abatacept or~* Methotrexate or leflunomide + rituximab or~* Methotrexate or leflunomide + tocilizumab or~* Methotrexate or leflunomide + sarilumab or~* Methotrexate or leflunomide + filgotinib or~* Methotrexate or leflunomide + upadacitinib or~* Methotrexate or leflunomide + Tofacitinib or~* Methotrexate or leflunomide + baricitinib"

DRUG

methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration

Trial Locations (1)

67098

RECRUITING

Hôpitaux Universitaires de Strasbourg, Strasbourg

All Listed Sponsors
lead

University Hospital, Strasbourg, France

OTHER